Continuing Education Activity

Scleredema of Buschke is a rare connective tissue disorder. Its pathogenesis is poorly understood. It belongs to the spectrum of scleroderma-like disorders. This activity reviews the evaluation and management of scleredema and highlights the role of the interprofessional team in evaluating and treating patients with Scleredema of Buschke.

Objectives:

• Identify the etiology of scleredema of Buschke medical conditions and emergencies.
• Review the appropriate history, physical, and evaluation of scleredema of Buschke.
• Outline the treatment and management options available for scleredema of Buschke.
• Describe interprofessional team strategies for improving care coordination and communication to advance scleredema of Buschke and improve outcomes.

Introduction

Scleredema of Buschke is a rare pathological condition of connective tissue. Its pathogenesis is poorly understood. First described by Curizo in 1752, the disease was well defined afterward by Buschke in 1902. It belongs to the spectrum of scleroderma-like disorders. Clinically, it is responsible for a fibro-mucinous progressive induration of the skin, involving the neck, shoulders and proximal upper members and eventually the face.[1] It occurs most commonly following an infectious episode. It has also been linked to diabetes mellitus and more rarely to hematological disorders. Histological features include dermal fibrosis with thickened collagen bundles and variable amounts of mucin deposits.[2]

Etiology

The scleredema of Buschke was classified into three types by Graff in 1968.

• Scleredema type 1 is the largest group and affects about 55% of the cases. It presents mostly in the pediatric population and young adults. Typically, the onset of scleredema is abrupt and starts after 2 to 3 weeks following a febrile infectious episode, usually streptococcal throat infection and less commonly a viral illness.[3]
• Scleredema type 2 encompasses about 25% of all cases. It demonstrates an insidious onset and progresses slowly, and correlates to hematological abnormalities. Paraproteinaemia is the most associated condition and always develops many years after the onset of scleredema. It occurs at a younger age when compared to the general population. Other abnormalities include monoclonal gammopathy of undetermined significance involving IgG and IgA, multiple myeloma and amyloidosis. The link between scleredema and paraprotein remains unclear.[2]
• Scleredema type 3 is referred to as scleredema diabeticorum since it involves diabetic patients.  It constitutes around 20% of cases. It is a known complication of long-lasting and poorly-controlled insulin-dependent diabetes mellitus. Severe diabetic vascular complications are usually associated. It affects 2.5% to 14% of all diabetic patients. There is a hypothesis that high glucose levels induce nonenzymatic glycosylation of collagen in the dermis.[4]

Other diseases have descriptions associated with the presentation scleredema of Buschke. They include primary hyperparathyroidism, rheumatoid arthritis, ankylosing spondylitis, Sjogren syndrome, dermatomyositis, Waldenstrom macroglobulinemia, anaphylactoid purpura, primary biliary cirrhosis, and IgA deficiency.[2] Cases of concomitant lichen sclerosus and atrophicus and scleredema adultorum of Buschke had been reported, endorsing the theory that scleroderma-like disorders share common underlying pathogenesis.[5] Rare cases of scleredema of Buschke have carry associations with concomitant neoplasms.[6]

Epidemiology

The exact incidence of scleredema of Buschke is unknown. The disease can occur at any age. There is no racial predilection. The first group mostly involves children and young adults — the second and third types of scleredema concern elderly patients (over forty years old). Male predominance is noted in type 1 and type 2 sclerema (sex-ratio around 2). In contrast, the male to female ratio approaches 10 to 1 in type 3.

Pathophysiology

Scleredema of Buschke is a skin connective tissue disease of unknown pathogenesis. Increased production of collagen type 1 and glycosaminoglycans by fibroblasts of the reticular dermis presented, as well as deposition of mucopolysaccharides in the interfibrillar spaces in the dermis. This phenomenon may become triggered by diverse stimuli, including infections, drugs, immunoglobulins, genetic factors, hyperinsulinism, and inflammatory processes.[7]

Histopathology

The skin biopsy is not required to confirm the diagnosis, but it is useful to exclude other scleroderma-like disorders. Histologic examination of the mid and the reticular dermis shows marked thickening of the collagen bundles, separated from one another by prominent, clear mucin-filled spaces. A mild mononuclear inflammatory infiltrates surrounding capillaries are observable. The subcutaneous fat shows invasions with enlarged collagen fibers. No abnormalities of the epidermis, the sweat glands or the pilosebaceous glands are present. Mucin deposits are observed in most cases, using Alcian blue or toluidine blue stains.[8]

History and Physical

The scleredema of Buschke Type 1 has an abrupt onset. The occurrence of febrile illness in the past 2 to 3 weeks should guide the diagnosis. In contrast, type 2 and 3 have a progressive course and diagnosis delays in most cases for several years. Transient erythema or annular rash may precede skin induration. The scleredema may cause pruritus and less commonly, pain. Patients usually complain about the limited motion of the shoulders and the temporomandibular joint with difficulty of mastication.

Physical examination shows a poorly-defined woody and non-pitting induration of the skin, with inconstant overlying erythema or hyperpigmentation. It first involves the neck and then spreads to the shoulders, the upper trunk, and the arms symmetrically. It can reach the face, and rarely the buttocks and thighs. Interestingly, the swelling spares the hands and feet. The affected skin has a ‘peau d’orange’ appearance when pinched.[2] There are reports of diffuse forms involving the whole dermis.[3] Unusual presentations include asymptomatic bilateral eyelid edema of sudden onset, presenting as periorbital edematous swelling.[1][9]

Extra-cutaneous involvement is exceptional, especially in types 2 and 3 scleredema. It affects mostly the tongue and the heart, but also the lungs, skeletal muscles, esophagus, parotid glands, liver, spleen, pleurae, and eyes. Complications include restricted motility, dysphagia, sicca syndrome, pleural or pericardial or peritoneal effusions. Symptoms of malignancies or complicated diabetes require careful vigilance.[2]

Evaluation

The diagnosis of scleredema has its basis in clinical and histological characteristics. No laboratory tests or immunological examinations are needed. It is recommended to perform a screening for paraproteins to identify a lymphoproliferative disorder.[10] The skin thickness may be measured using ultrasonography. It helps to evaluate the activity and severity of the disease.[11]

Treatment / Management

There is no specific therapy for scleredema of Buschke. Various therapeutic alternatives are proposed to alleviate the symptoms. Phototherapy represents first-line treatment. In unresponsive or severe cases, intravenous immunoglobulin is a recommended option.[12][13][14]

Treatment of the underlying cause is required. In scleredema type 1, antibiotics are indicated in the case of streptococcic infection. Patients of type 2 require management by a hematologist. Tight control of diabetes in urged for patients of type 3, although there is no clear improvement of scleredema. Other therapies include steroids, cyclosporine, penicillamine, cyclophosphamide, electron beam therapy, high doses of intravenous penicillin.[2] However, no approach had shown consistent results, and most patients describe partial remission. Physical therapy is a recommendation for patients with limited mobility caused by scleredema.

Differential Diagnosis

All diseases sharing with edema and mucin deposition must merit consideration among the differential diagnosis of scleredema of Buschke. It is commonly confused with scleromyxedema and scleroderma disorders.

Scleroderma is usually observed in systemic sclerosis and typically presents as asymmetrical thickening of the skin with pigmentation and centripetal progression. Typically, there system involvement and presence of scleroderma-specific autoantibodies, Raynaud phenomenon, and nail fold capillary abnormalities. Histopathology shows excessive collagen resulting in the thickened dermis. The distinction between scleredema and scleroderma usually has a basis on clinical features, rather than histological findings.

Scleromyxedema is also a scleroderma-like disorder. They both share the mucin dermal deposition and development of paraproteinemia. Scleromyxedema presents as cutaneous lichenoid papules that extend and form hardened plaques involving the face, the neck, and the arms and can be generalized. Unlike scleredema, it affects the hands and the fingers. Histologically it is characterized by dermal fibrosis with dermal fibers separated by excessive mucin deposits composed mainly of hyaluronic acid. Systemic involvement is common, secondary to mucin deposits. It may also be associated with monoclonal gammopathy, multiple myeloma, and thyroid dysregulation.[8]

Prognosis

The prognosis of the scleredema of Buschke highly depends on the subtype. In type 1 patients, the scleredema is self-limiting and usually resolves spontaneously within 6 to 24 months. Reports exist of longer course up to ten years. In type 2 and 3, the disease progresses slowly with possible systemic involvement and life-threatening complications.

Enhancing Healthcare Team Outcomes

Pediatric scleredema is an uncommon and under-recognized disorder. An enhanced education program about the disease is required, especially among pediatricians, primary care providers, and nurse practitioners. The primary clinician may not know how to manage the disorder, but they should know when to refer the patient to a dermatologist. Without the benefit of controlled trials, the treatment remains empirical and based on personal experience. The pharmacist should educate the patient on the different medications used to treat the disorder and their potential side effects, as well as performing medication reconciliation to avoid any drug-drug interactions. Concerns should be reported to the clinician managing the patient. Patients should have screening for diabetes and hematological malignancies. Because many patients develop anxiety and depression, a mental health nurse should counsel these patients. Nursing can also monitor for treatment effectiveness and inquire regarding potential medication side effects, reporting these to the healthcare team. Open communication and collaboration between members of the interprofessional team are necessary to achieve good outcomes. [Level V]

Parents should receive reassurance about the positive prognosis of the condition. Scleredema in types 2 and 3 is a chronic and debilitating disorder. Long-term periodic screening for paraprotein is mandatory in types 2 and 3.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Fania L, Colonna L, Pagnanelli G, Abeni D, Annessi G, Mazzanti C. Scleredema of Buschke with prominent periorbital edema. Int J Dermatol. 2017 Oct;56(10):e193-e194. [PubMed: 28464273]

2.

Rongioletti F, Kaiser F, Cinotti E, Metze D, Battistella M, Calzavara-Pinton PG, Damevska K, Girolomoni G, André J, Perrot JL, Kempf W, Cavelier-Balloy B. Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2399-404. [PubMed: 26304054]

3.

Shrestha B, Neopane AK, Panth R. Scleredema--an uncommon cause of swelling in a child--a case report and review of the literature. BMC Res Notes. 2014 Aug 27;7:571. [PMC free article: PMC4153942] [PubMed: 25159854]

4.

Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am. 2013 Dec;42(4):869-98. [PubMed: 24286954]

5.

Venturi M, Damevska K, Ferreli C, Pinna AL, Atzori L, Gocev G, Rongioletti F. Scleredema of Buschke associated with lichen sclerosus: Three cases. Indian J Dermatol Venereol Leprol. 2020 May-Jun;86(3):272-277. [PubMed: 30289118]

6.

Manchanda Y, Das S, Sharma VK, Srivastava DN. Scleredema associated with carcinoma of the gall bladder. Br J Dermatol. 2005 Jun;152(6):1373-4. [PubMed: 15949020]

7.

Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. J Mol Med (Berl). 2014 Sep;92(9):913-24. [PubMed: 25030650]

8.

Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep. 2012 Feb;14(1):39-46. [PubMed: 22131103]

9.

Ioannidou DI, Krasagakis K, Stefanidou MP, Karampekios S, Panayiotidis J, Tosca AD. Scleredema adultorum of Buschke presenting as periorbital edema: a diagnostic challenge. J Am Acad Dermatol. 2005 Feb;52(2 Suppl 1):41-4. [PubMed: 15692512]

10.

Alter D. Laboratory Testing in the Setting of Diabetic Scleredema. JAMA. 2016 Aug 02;316(5):542. [PubMed: 27483073]

11.

Ha DH, Lee MJ, Kim SJ. Ultrasonographic Findings of Scleredema Adultorum of Buschke Involving the Posterior Neck. Korean J Radiol. 2018 May-Jun;19(3):425-430. [PMC free article: PMC5904469] [PubMed: 29713220]

12.

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1581-1594. [PubMed: 28786499]

13.

Emre S. Intravenous immunoglobulin treatment: Where do dermatologists stand? Dermatol Ther. 2019 May;32(3):e12854. [PubMed: 30756448]

14.

Eastham AB, Femia AN, Velez NF, Smith HP, Vleugels RA. Paraproteinemia-associated scleredema treated successfully with intravenous immunoglobulin. JAMA Dermatol. 2014 Jul;150(7):788-9. [PubMed: 24847975]

Disclosure: Asma Raboudi declares no relevant financial relationships with ineligible companies.

Disclosure: Noureddine Litaiem declares no relevant financial relationships with ineligible companies.